Skip directly to content

Centre for Therapeutic Innovation

The Centers for Therapeutic Innovation (CTI) facilitate authentic collaboration between Pfizer scientists and select academic medical centres, disease foundations, and the National Institutes of Health. The aim is to translate promising science into clinical candidates. Pfizer Inc. has CTI labs in San Francisco, New York, Boston and San Diego.

These state-of-the-art laboratories are populated with Pfizer scientists and post-docs who are creating and advancing novel therapeutics, with the goal of moving the therapeutics rapidly into first-in-human proof of mechanism studies. CTI’s research collaborators work side-by-side with Pfizer scientists in the discovery and development of new therapies for unmet medical needs. For more information visit:

Unprecedented Access and Authentic Collaboration

As part of the CTI, an entrepreneurial group within Pfizer partners with leading academic centres and disease foundations with the aim of translating promising science into clinical candidates. Partners are given unprecedented access to our antibody/small molecule library and technologies, and can draw upon Pfizer’s expertise.

Authentic collaboration includes:

  • shared decision making

  • shared accountability

    • each project is overseen by a joint steering committee to evaluate the success of the program and monitor progress toward milestones

  • alignment on incentives

    • joint IP and ownership, broad rights to publication, milestone payments and royalties for successful programs